AI Transforming Precision Medicine
How AI-Driven Data Curation is Transforming Precision Medicine Precision medicine—a healthcare approach that personalizes disease prevention and treatment based on insights into a patient’s genes, environment, and behavior—holds incredible promise. However, its success depends on high-quality, curated data from sources like electronic health records (EHRs). This reliance creates significant challenges for healthcare providers and researchers. Can artificial intelligence (AI) help address these hurdles? AI-enabled data curation is already making strides in advancing precision medicine, particularly in oncology. By analyzing vast datasets, including structured and unstructured information, AI is helping healthcare organizations accelerate research and improve patient outcomes. Data Curation Challenges in Precision Medicine Real-world data (RWD) is a key driver of precision medicine, but processing this data is fraught with challenges. According to Dr. C.K. Wang, Chief Medical Officer at COTA, Inc., EHRs provide unprecedented access to detailed patient information, enabling deeper insights into care patterns. However, much of this data resides in unstructured formats, such as clinicians’ notes, making it difficult to extract and analyze. “To transform this unstructured data into actionable insights, significant human expertise and resources are required,” Wang explained. While AI tools like COTA’s CAILIN, which uses advanced search capabilities, streamline this process, human involvement remains essential. Wang emphasized that even with the rapid advancements in AI, healthcare data curation requires expert oversight to ensure quality and reliability. “The adage ‘junk in, junk out’ applies here—without high-quality training data, AI cannot generate meaningful insights,” he noted. PHI and COTA: A Collaborative Approach to AI-Driven Curation To overcome these challenges, Precision Health Informatics (PHI), a subsidiary of Texas Oncology, partnered with COTA to enhance their data curation capabilities. The collaboration aims to integrate structured and unstructured data, including clinician notes and patient-reported outcomes, into a unified resource for precision medicine. PHI’s database, which represents 1.6 million patient journeys, provides a rich resource for hypothesis-driven studies and clinical trial enrichment. However, much of this data was siloed or unstructured, requiring advanced tools and expert intervention. Lori Brisbin, Chief Operating Officer at PHI, highlighted the importance of partnering with a data analytics leader. “COTA’s strong clinical knowledge in oncology allowed them to identify data gaps and recommend improvements,” she said. This partnership is yielding significant results, including a high data attrition rate of 87%—far surpassing the industry average of 50% for similar projects. The Role of AI in Cancer Care AI tools like CAILIN are helping PHI and COTA refine data curation processes by: Brisbin likened the role of AI to sorting images: “If you’re looking for German shepherds, AI will narrow the search but might include similar images, like wolves or huskies. Experts are still needed to validate and refine the results.” Building the Foundation for Better Outcomes The integration of high-quality RWD into analytics efforts is reshaping precision medicine. While clinical trial data offers valuable insights, it often lacks the variability seen in real-world scenarios. Adding RWD to these datasets helps expand the scope of research and ensure broader applicability. For instance, cancer care guidelines developed with RWD can account for diverse patient populations and treatment approaches. COTA’s work with PHI underscores the value of collaborative data curation, with AI streamlining processes and human experts ensuring accuracy. The Future of AI in Precision Medicine As healthcare organizations invest in data-driven innovation, AI will play an increasingly pivotal role in enabling precision medicine. However, challenges remain. Wang noted that gaps in EHR data, such as missing survival metrics, can undermine oncological outcomes research. Advances in interoperability and external data sources will be key to addressing these issues. “The foundation of our partnership is built on leveraging data insights to enhance care quality and improve operational efficiency,” Wang said. Through AI-powered tools and meaningful partnerships, precision medicine is poised to deliver transformative results, empowering providers to offer tailored treatments that improve patient outcomes at scale. Like Related Posts Who is Salesforce? Who is Salesforce? Here is their story in their own words. From our inception, we’ve proudly embraced the identity of Read more Salesforce Unites Einstein Analytics with Financial CRM Salesforce has unveiled a comprehensive analytics solution tailored for wealth managers, home office professionals, and retail bankers, merging its Financial Read more AI-Driven Propensity Scores AI plays a crucial role in propensity score estimation as it can discern underlying patterns between treatments and confounding variables Read more Tectonic’s Successful Salesforce Track Record Salesforce Technology Services Integrator – Tectonic has successfully delivered Salesforce in a variety of industries including Public Sector, Hospitality, Manufacturing, Read more

















